This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Correction: Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)

Published: March 15, 2014

This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

doi:10.4088/JCP.13lcx08958).

Correction

In the article “Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)” by Richard H. Weisler, MD, and colleagues in the November 2011 issue (J Clin Psychiatry 2011;72[11]:1452-1464), in Figure 2 on page 1456, the number of patients randomized to quetiapine who discontinued due to mood event should be n = 87.

The staff regret the error. The online article at PSYCHIATRIST.COM has been corrected.

Volume: 75

Quick Links: Bipolar Disorder

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...